DKK670.2m market cap
DKK4.05 last close
BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.
Investment summary
BioPorto’s lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The test is currently completing pivotal clinical trials for adults in plasma and for children in urine. Two 510(k)’s will be submitted to the FDA for approval in 2019. The NGAL test is commercially available for research purposes in the US and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.
Y/E Dec |
Revenue (DKKm) |
EBITDA (DKKm) |
PBT (DKKm) |
EPS (ore) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 25.2 | (33.1) | (34.2) | (20.59) | N/A | N/A |
| 2018A | 26.0 | (42.1) | (42.5) | (24.34) | N/A | N/A |
| 2019E | 38.6 | (40.7) | (40.7) | (20.98) | N/A | N/A |
| 2020E | 53.7 | (46.2) | (46.4) | (22.80) | N/A | N/A |
| Last updated on 21/03/2019 | ||||||
Industry outlook
The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.
Last updated on 21/03/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (DKKm) | 11.5 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Thomas Magnussen | Chairman |
| Peter Mørch Eriksen | CEO |
| Ole Larsen | CFO |
| Jan Kuhlmann Andersen | COO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma